Discovery of molecular signatures to understand the response of Immuno-oncology drugs
Not Applicable
- Registration Number
- CTRI/2023/09/057273
- Lead Sponsor
- Strand Life Sciences Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with confirmed malignant carcinoma as defined above who are eligible for mono-immuno-oncology therapy and will undergo the treatment, as identified by the site Principal Investigator or Co-Investigators through routine clinical care processes
Age - 18 years and above
Both men and women of all races and ethnic groups are eligible for this study
New, relapsed, recurrent or metastatic cases
Ability to understand and the willingness to sign a written Informed Consent Form
Exclusion Criteria
Pregnant or lactating women
Patients who have untreated active infection
Patients who are receiving any additional oncology investigational agent(s) with immuno-oncology drugs
Patients undergoing combinatorial immunotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of signature biomarkers via a minimally invasive procedure will enable distinguishing between mono immunooncology drug responder & nonresponder or patient prognosis while on mono immunotherapy for cancer.Timepoint: 13 (before therapy starts and every month for period of 12 months)
- Secondary Outcome Measures
Name Time Method Identification of reliable predictive molecular markers to distinguish responders & non-responders for immuno-oncology drugsTimepoint: 13 (before therapy starts & every month for period of 12 months)